BRAF and melanoma: Second, the singular focus on KRAS-centric pathways, although justified by emerging evidence of KRAS involvement in some melanomas, may overlook synergistic or compensatory signaling through parallel oncogenic axes such as those governed by BRAF, NRAS, or PI3K-AKT-mTOR (68).